Last reviewed · How we verify
Healive® Lot 3
Healive is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
Healive is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection in children and adults.
At a glance
| Generic name | Healive® Lot 3 |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus particles that trigger both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HAV IgG) and memory B cells, conferring long-term immunity against hepatitis A infection. The inactivated virus cannot cause disease but effectively primes the immune system for recognition and neutralization of wild-type virus.
Approved indications
- Prevention of hepatitis A infection in children and adults
Common side effects
- Injection site pain or soreness
- Fever
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Healive® Lot 3 CI brief — competitive landscape report
- Healive® Lot 3 updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI